IP Library › Patent Application 16504602
Patent Application
App. No. 16/504,602

ANTI-NGF COMPOSITIONS AND USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/504,602
Abstract

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

Claims (146)

1 . An anti-human NGF antibody or antibody fragment which comprises the same CDR polypeptides as an anti-human NGF antibody selected from Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, Ab14, Ab15, Ab16, Ab17, Ab18, Ab19, Ab20, and Ab21.

2 - 5 . (canceled)

6 . The anti-human NGF antibody or fragment according to claim 1 , wherein said fragment is a Fab fragment comprising a V H polypeptide at least 90% identical to one selected from those in SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 143, 153, 163, 173, 183, 193, or 402 and/or V L polypeptide sequence at least 90% identical to one selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 161, 171, 181, 191, or 401.

7 - 21 . (canceled)

22 . The anti-human NGF antibody or fragment of claim 1 , which is directly or indirectly attached to a detectable label or therapeutic agent.

23 . A nucleic acid sequence or nucleic acid sequences which result in the expression of an anti-human NGF antibody or antibody fragment according to claim 1 .

24 - 26 . (canceled)

27 . A recombinant cell which expresses an antibody or antibody fragment according to claim 1 .

28 - 31 . (canceled)

32 . A method of treatment comprising administering to a patient with a disease or condition associated with NGF expressing cells a therapeutically effective amount of at least one anti-human NGF antibody or fragment according to claim 1 .

33 . The method of claim 32 wherein the disease is selected from inflammatory pain, post-operative incision pain, complex regional pain syndrome, cancer pain, primary or metastatic bone cancer pain, fracture pain, osteoporotic fracture pain, pain resulting from burn, osteoporosis, gout joint pain, pain associated with sickle cell crises, and other nociceptic pain, as well as hepatocellular carcinoma, breast cancer, liver cirrhosis, neurogenic pain, neuropathic pain, nociceptic pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, fibromyalgia, menstrual pain, ovarialgia, reflex sympathetic dystrophy, neurogenic pain, osteoarthritis or rheumatoid arthritis pain, lower back pain, diabetic neuropathy, sciatica, or migraine.

34 - 57 . (canceled)

58 . A method of making an antibody according to claim 1 , in a recombinant host cell or non-human transgenic animal or plant containing one or more heterologous polynucleotides encoding said antibody.

59 - 117 . (canceled)

118 . An anti-NGF antibody or antibody fragment according to claim 1 , comprising a variable light chain polypeptide sequence and a variable heavy chain polypeptide sequence selected from the following:

Variable Light

Variable Heavy

Chain

Chain

A

Seq ID No: 1 

Seq ID No: 3 

B

Seq ID No: 11 

Seq ID No: 13 

C

Seq ID No: 21 

Seq ID No: 23 

D

Seq ID No: 31 

Seq ID No: 33 

E

Seq ID No: 41 

Seq ID No: 43 

F

Seq ID No: 51 

Seq ID No: 53 

G

Seq ID No: 61 

Seq ID No: 63 

H

Seq ID No: 71 

Seq ID No: 73 

I

Seq ID No: 81 

Seq ID No: 83 

J

Seq ID No: 91 

Seq ID No: 93 

K

Seq ID No: 101

Seq ID No: 103

L

Seq ID No: 111

Seq ID No: 113

M

Seq ID No: 121

Seq ID No: 123

N

Seq ID No: 131

Seq ID No: 133

O

Seq ID No: 141

Seq ID No: 143

P

Seq ID No: 151

Seq ID No: 153

Q

Seq ID No: 161

Seq ID No: 163

R

Seq ID No: 171

Seq ID No: 173

S

Seq ID No: 181

Seq ID No: 183

T

Seq ID No: 191

Seq ID No: 193

119 . An anti-NGF antibody or antibody fragment according to claim 1 , comprising a light chain polypeptide sequence and a heavy chain polypeptide sequence selected from the following:

Light Chain

Heavy Chain

Ab1 

Seq ID No: 2 

Seq ID No: 4 

Ab2 

Seq ID No: 12 

Seq ID No: 14 

Ab3 

Seq ID No: 22 

Seq ID No: 24 

Ab4 

Seq ID No: 32 

Seq ID No: 34 

Ab5 

Seq ID No: 42 

Seq ID No: 44 

Ab6 

Seq ID No: 52 

Seq ID No: 54 

Ab7 

Seq ID No: 62 

Seq ID No: 64 

Ab8 

Seq ID No: 72 

Seq ID No: 74 

Ab9 

Seq ID No: 82 

Seq ID No: 84 

Ab10

Seq ID No: 92 

Seq ID No: 94 

Ab11

Seq ID No: 102

Seq ID No: 104

Ab12

Seq ID No: 112

Seq ID No: 114

Ab13

Seq ID No: 122

Seq ID No: 124

Ab14

Seq ID No: 132

Seq ID No: 134

Ab15

Seq ID No: 142

Seq ID No: 144

Ab16

Seq ID No: 152

Seq ID No: 154

Ab17

Seq ID No: 162

Seq ID No: 164

Ab18

Seq ID No: 172

Seq ID No: 174

Ab19

Seq ID No: 182

Seq ID No: 184

Ab20

Seq ID No: 192

Seq ID No: 194

Ab21

Seq ID No: 401

Seq ID No: 402

120 - 144 . (canceled)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2020
From: ALDERBIO HOLDINGS LLC
To: H. LUNDBECK A/S
Reel/Frame 053020/0331 →